STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
Hazel Tye, Catherine L Kennedy, Meri Najdovska, Louise McLeod, William McCormack, Norman Hughes, Anouk Dev, William Sievert, Chia Huey Ooi, Tomo-o Ishikawa, Hiroko Oshima, Prithi S Bhathal, Andrew E Parker, Masanobu Oshima, Patrick Tan, Brendan J Jenkins
Cancer Cell | CELL PRESS | Published : 2012
Awarded by Grants-in-Aid for Scientific Research
We thank E. Vidacs and M. Meilak for technical assistance and N. Watkins and P. Hertzog for critical reading of the manuscript. We are grateful to S. Akira and S. Uematsu (University of Osaka, Japan) for kindly providing the Tlr2<SUP>-/-</SUP> and Tlr4<SUP>-/-</SUP> mice. This work was supported by grants from the Association for International Cancer Research (U.K.), Cancer Council of Victoria (Australia), and the National Health and Medical Research Council (Australia), as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. B.J.J. is supported by both a Senior Medical Research Fellowship awarded by the Sylvia and Charles Viertel Foundation and a Monash University Fellowship. We also acknowledge the generosity of the family and friends of the late L. Hender for supporting cancer research. W.M. is a current employee and A.E.P. is a former employee and shareholder of Opsona Therapeutics, a drug discovery and development company focused on the role of TLR signaling in human immunology.